Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,271
Employees1,271
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,271
Employees1,271

INSM Key Statistics

Market cap
33.89B
Market cap33.89B
Price-Earnings ratio
-25.27
Price-Earnings ratio-25.27
Dividend yield
Dividend yield
Average volume
3.27M
Average volume3.27M
High today
$159.75
High today$159.75
Low today
$153.09
Low today$153.09
Open price
$154.63
Open price$154.63
Volume
167.36K
Volume167.36K
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

With a market cap of 33.89B, Insmed Incorporated(INSM) trades at $158.93. The stock has a price-to-earnings ratio of -25.27.

During the trading session on 2026-01-26, Insmed Incorporated(INSM) shares reached a daily high of $159.75 and a low of $153.09. At a current price of $158.93, the stock is +3.8% higher than the low and still -0.5% under the high.

Trading volume for Insmed Incorporated(INSM) stock has reached 167.36K, versus its average volume of 3.27M.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

INSM News

TipRanks 4d
Insmed initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Insmed (INSM) with a Buy rating and $212 price target The firm believes the company is well positioned for share upside in 20...

Simply Wall St 4d
Did Insmed’s ARIKAYCE and BRINSUPRI Surge Just Recast Its Investment Narrative?

In January 2026, Insmed reported strong preliminary 2025 results, with total revenue rising to US$606.4 million from US$363.7 million a year earlier, fueled by...

Did Insmed’s ARIKAYCE and BRINSUPRI Surge Just Recast Its Investment Narrative?
Simply Wall St 5d
Assessing Insmed’s Valuation After Upbeat 2025 Outlook And 2026 Pipeline Targets

Advertisement Why Insmed’s latest update matters for shareholders Insmed (INSM) recently issued preliminary 2025 figures and fresh guidance, highlighting reve...

Assessing Insmed’s Valuation After Upbeat 2025 Outlook And 2026 Pipeline Targets

Analyst ratings

95%

of 21 ratings
Buy
95.2%
Hold
4.8%
Sell
0%

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.